Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric diseases and disorders in the United States. The company is headquartered in San Diego, California.
| Revenue (TTM) | $3.10B |
| Gross Profit (TTM) | $2.00B |
| EBITDA | $828.60M |
| Operating Margin | 22.80% |
| Return on Equity | 22.50% |
| Return on Assets | 11.60% |
| Revenue/Share (TTM) | $31.12 |
| Book Value | $33.87 |
| Price-to-Book | 5.21 |
| Price-to-Sales (TTM) | 5.93 |
| EV/Revenue | 5.42 |
| EV/EBITDA | 20.31 |
| Quarterly Earnings Growth (YoY) | 2311.00% |
| Quarterly Revenue Growth (YoY) | 42.20% |
| Shares Outstanding | $100.55M |
| Float | $99.30M |
| % Insiders | 1.08% |
| % Institutions | 104.29% |
Volatility is currently expanding
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Neurocrine (NBIX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2026.
NBIX heads into Q2 results with a focus on Ingrezza sales, Crenessity growth and pipeline updates as investors watch key commercial and clinical progress.
SAN DIEGO, July 23, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of three Senior Vice Presidents, further strengthening its leadership team as the company executes its next phase of growth, expands its commercial portfolio and advances one of the industry's strongest neuroscience pipelines. These appointments reflect Neurocrine's continued evolution into a diversified, multi-product biopharmaceutical company positioned to deliver sustainable long-term growth.
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, July 21, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Samir Siddhanti as Chief Business Officer and a member of the company's executive Management Committee. As Chief Business Officer, Siddhanti will lead Neurocrine's enterprise growth strategy, overseeing business development, corporate strategy, alliance management and program management to maximize the value of the company's expanding pipeline through both internal innovation and strategic external opportunities.
NVIDIA, Neurocrine and Ball screen well for earnings growth and rising estimates, highlighting stocks with improving profit expectations.
Neurocrine Biosciences (NBIX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the market.
Biopharmaceutical firm Neurocrine Biosciences, Inc. (NBIX) up over 35% in a year and 17% since outlier inflows in May.
Conference Call and Webcast Scheduled for Thursday, July 30 SAN DIEGO, July 9, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter 2026 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on NBIX and any ticker you trade — then tracks every position and per-strategy win rate.
